The role of gut dysbiosis in endocrine and metabolic derangements of chronic kidney disease: mechanisms, controversies, and future perspectives - Report - MDSpire
Advertisement
The role of gut dysbiosis in endocrine and metabolic derangements of chronic kidney disease: mechanisms, controversies, and future perspectives
Clinical Report: The Impact of Gut Dysbiosis on Endocrine and Metabolic Imbalances in CKD
Overview
This mini-review highlights the role of gut dysbiosis as a significant factor in the progression of chronic kidney disease (CKD) and its associated endocrine and metabolic complications. It discusses how alterations in gut microbiota contribute to the accumulation of uremic toxins and the depletion of beneficial metabolites, exacerbating systemic inflammation and metabolic dysregulation.
Background
Chronic kidney disease (CKD) affects approximately 10% of the global population and is associated with various endocrine and metabolic disorders that increase cardiovascular risk and mortality. The gut microbiota has emerged as a critical player in CKD pathophysiology, influencing disease progression through the gut–kidney axis. Understanding the mechanisms by which gut dysbiosis impacts CKD is essential for developing targeted therapeutic strategies.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
Gut dysbiosis in CKD is characterized by an increase in uremic toxin-producing bacteria and a decrease in beneficial metabolite-producing species.
Dysbiosis contributes to the accumulation of gut-derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate.
Alterations in gut microbiota exacerbate systemic inflammation, oxidative stress, and endocrine–metabolic dysregulation.
Current controversies include the definition of dysbiosis and the role of dietary interventions in managing CKD.
Practical dietary approaches may help translate mechanistic findings into clinical practice for CKD management.
Clinical Implications
A better understanding of the gut microbiota's role in CKD may inform dietary strategies and microbiota-targeted therapies. Addressing gut dysbiosis could potentially mitigate endocrine and metabolic complications in CKD patients.
Conclusion
Gut dysbiosis is a relevant and potentially modifiable factor in the progression of CKD and its complications. Further research is needed to clarify the mechanisms and therapeutic implications of gut microbiota alterations in this patient population.
